G-CSF and GM-CSF Repurposing for Pancreatic and Colon Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments for pancreatic and colon cancers are ineffective and often result in severe side effects due to non-selective targeting of cancer cells, leading to high mortality rates and significant healthcare costs, with existing therapies like GM-CSF and G-CSF showing detrimental effects in some cases.
Innovation Solution
Administering exogenous G-CSF or GM-CSF as soluble active pharmaceutical ingredients to induce neutrophilia, leveraging their chemotherapeutic potential to slow down cancer progression in colon and pancreatic cancers, repurposing these recombinant proteins as antineoplastic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exogenous G-CSF or GM-CSF is administered to induce neutrophilia, then anti-tumor activity is enhanced and cancer progression is slowed, but the risk of promoting tumor growth through vascularization stimulation increases
Solution Approach 1:
The patent applies parameter changes by modifying the dosing regimen, administration frequency, and duration of G-CSF/GM-CSF therapy to optimize the balance between anti-tumor efficacy and vascularization risk. By adjusting these parameters, the treatment achieves therapeutic benefit while minimizing harmful effects.
Solution Approach 2:
The patent employs periodic action through intermittent dosing schedules and cycling therapy regimens. This approach allows periods of treatment followed by rest intervals, preventing continuous stimulation of tumor vascularization while maintaining anti-tumor activity through repeated neutrophil mobilization events.
2Reliability
If non-selective cytotoxic chemotherapy is used to impair cancer cell division, then cancer cell proliferation is reduced, but normal dividing cells such as neutrophils are also damaged causing neutropenia
Solution Approach 1:
The patent converts the harmful effect of chemotherapy-induced neutropenia into a beneficial therapeutic mechanism. By administering G-CSF or GM-CSF after chemotherapy, the treatment deliberately induces controlled neutrophil depletion followed by robust rebound, utilizing the neutrophil-mediated immune response to attack tumor cells.
Solution Approach 2:
The patent introduces G-CSF or GM-CSF as an intermediary substance that mediates between chemotherapy treatment and neutrophil recovery. These colony-stimulating factors act as biological intermediaries that accelerate neutrophil regeneration and modulate the immune response, bridging the gap between cancer cell killing and normal cell recovery.
3Reliability
If new cancer biological therapies are developed to treat specific cancer types, then therapeutic efficacy is improved, but development costs increase to approximately 1.2 billion dollars per drug
Solution Approach 1:
The patent applies universality by demonstrating that existing approved drugs (G-CSF and GM-CSF), originally developed for a single indication (chemotherapy-induced neutropenia), can be repurposed for multiple cancer types including pancreatic and colon cancer. This multi-functional use of existing drugs avoids the need for expensive de novo drug development while maintaining therapeutic efficacy.
Solution Approach 2:
The patent employs copying by leveraging the established safety profile, pharmacokinetic data, and manufacturing processes of existing G-CSF and GM-CSF formulations. Rather than creating entirely new molecules, the invention copies and adapts proven therapeutic agents for new indications, significantly reducing development costs and regulatory hurdles.
Data Source
AI summary
There is provided a Colony Stimulating Factor (CSF) as an active ingredient for use in the treatment of colon or pancreatic cancer through an increase in neutrophilia, wherein the Colony Stimulating Factor is selected from the group consisting of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF). The new use for these two recombinant proteins represents a new treatment option for two of the most frequent forms of cancer.